WHWK

Whitehawk Therapeutics Inc

Mar 19 • 04:00PM ET

3.59

-0.22 -5.77 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD BMRN RARE ARGX AGIO AFMD AMRN ATRA ADAP VIVS

Index	-	P/E	7.57	EPS (ttm)	0.47	Insider Own	44.40%	Shs Outstand	47.15M	Perf Week	-7.95%
Market Cap	169.44M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-0.05%	Shs Float	26.24M	Perf Month	19.67%
Enterprise Value	23.74M	PEG	-	EPS next Q	-0.01	Inst Own	54.11%	Short Float	2.98%	Perf Quarter	49.58%
Income	-20.60M	P/S	23.73	EPS this Y	-275.76%	Inst Trans	5.89%	Short Ratio	5.32	Perf Half Y	84.10%
Sales	7.14M	P/B	1.24	EPS next Y	4.64%	ROA	-18.58%	Short Interest	0.78M	Perf YTD	48.35%
Book/sh	2.89	P/C	1.16	EPS next 5Y	-	ROE	-21.82%	52W High	4.48 -19.86%	Perf Year	77.72%
Cash/sh	3.09	P/FCF	-	EPS past 3/5Y	50.16% 58.28%	ROIC	-15.11%	52W Low	1.39 158.27%	Perf 3Y	-52.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-22.27% -13.29%	Gross Margin	89.06%	Volatility	5.80% 7.80%	Perf 5Y	-85.67%
Dividend TTM	-	EV/Sales	3.32	EPS Y/Y TTM	120.71%	Oper. Margin	-1601.12%	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.26	Sales Y/Y TTM	-72.50%	Profit Margin	-288.26%	RSI (14)	53.58	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.26	EPS Q/Q	50.21%	SMA20	0.39%	Beta	0.53	Target Price	5.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	15.36%	Rel Volume	1.56	Prev Close	3.81
Employees	23	LT Debt/Eq	0.00	Earnings	Mar 12 BMO	SMA200	54.71%	Avg Volume	146.69K	Price	3.59
IPO	Aug 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.55% -	Trades		Volume	228,483	Change	-5.77%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Initiated	Oppenheimer	Outperform	$6
Aug-27-24	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $1.75
Aug-21-24	Downgrade	TD Cowen	Buy → Hold
Aug-21-24	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-22	Initiated	Jefferies	Buy	$45
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy	$51
Sep-08-21	Initiated	Piper Sandler	Overweight	$45

Mar-17-26 04:30PM	Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 (PR Newswire)
Mar-12-26 08:00AM	Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights (PR Newswire)
Mar-03-26 01:30PM	Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 (MarketBeat)
Feb-26-26 08:00AM	Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-25-26 02:21PM	Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028 (MarketBeat) +5.77%
09:41AM	Loading…
Feb-18-26 09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
08:00AM	Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire)
Feb-13-26 09:33AM	Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release? (Zacks) -5.32%
Jan-08-26 08:00AM	Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 (PR Newswire)
Dec-01-25 08:00AM	Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer (PR Newswire)
Nov-26-25 08:00AM	Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire) +6.98%
Nov-11-25 08:00AM	Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London (PR Newswire)
Nov-06-25 08:00AM	Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire) -6.67%
Oct-24-25 12:30PM	Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC (PR Newswire)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks) -15.33%
08:30AM	Loading…
Oct-16-25 08:30AM	Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research (Business Wire) +24.29%
Sep-02-25 08:00AM	Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-12-25 05:32AM	US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche (GlobeNewswire)
Aug-07-25 08:00AM	Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Jul-22-25 08:00AM	Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (PR Newswire)
Jun-19-25 08:00AM	Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series (PR Newswire)
Jun-13-25 08:44AM	Implied Volatility Surging for Whitehawk Therapeutics Stock Options (Zacks)
May-28-25 08:00AM	Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference (PR Newswire)
May-21-25 08:00AM	Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit (PR Newswire)
May-08-25 04:05PM	Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Mar-26-25 08:00AM	Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals (PR Newswire)
Mar-19-25 11:52AM	Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript (SeekingAlpha)
Mar-14-25 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update (PR Newswire)
Mar-04-25 04:05PM	Aadi Bioscience Announces Closing of $100 Million PIPE Financing (PR Newswire)
Mar-03-25 08:00AM	Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders (PR Newswire) -10.16%
08:00AM	Loading…
Feb-24-25 08:00AM	Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference (PR Newswire)
Feb-18-25 08:00AM	Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer (PR Newswire)
Feb-05-25 04:05PM	Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 (PR Newswire) +6.23%
Dec-21-24 06:31AM	Aadi Biosciences Strategic Agreements and Funding Moves (TipRanks)
Dec-19-24 06:30PM	Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO and $100 Million PIPE Financing (PR Newswire) +46.12%
Nov-06-24 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update (PR Newswire) +6.53%
Oct-30-24 04:05PM	Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update (PR Newswire)
Aug-20-24 05:00PM	Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates (PR Newswire)
Aug-07-24 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update (PR Newswire)
Jul-31-24 04:05PM	Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update (PR Newswire)
Jul-05-24 01:07PM	3 Russell 2000 Stocks to Sell in July Before They Crash & Burn (InvestorPlace)
May-29-24 04:05PM	Aadi Bioscience to Participate in the Jefferies Healthcare Conference (PR Newswire) -6.38%
May-23-24 05:30PM	Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) -5.70%
May-09-24 01:52PM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 12:53PM	AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.80%
08:00AM	Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update (PR Newswire)
May-01-24 08:01AM	Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update (PR Newswire)
Apr-09-24 08:00AM	Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-03-24 09:40AM	Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-18-24 09:40AM	Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-17-24 08:00AM	Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) (PR Newswire)
Mar-15-24 10:43AM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.85%
Mar-13-24 09:05AM	Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +11.34%
08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update (PR Newswire)
Mar-06-24 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update (PR Newswire)
Mar-05-24 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire) -13.35%
Mar-01-24 04:08PM	Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa (PR Newswire) +26.82%
Feb-26-24 04:05PM	Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Jan-26-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (PR Newswire)
Jan-19-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium (PR Newswire)
Dec-15-23 09:14AM	Why Is Aadi Bioscience (AADI) Stock Down 56% Today? (InvestorPlace) -56.42%
Dec-14-23 04:05PM	Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations (PR Newswire)
Nov-08-23 08:46AM	Aadi Bioscience Q3 Loss Per Share Narrows (RTT News)
08:00AM	Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update (PR Newswire)
Nov-06-23 04:05PM	Aadi Bioscience to Participate in Jefferies London Healthcare Conference (PR Newswire)
Nov-01-23 04:05PM	Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update (PR Newswire) +6.48%
Oct-19-23 04:05PM	Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting (PR Newswire)
Oct-12-23 04:05PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-05-23 04:05PM	Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium (PR Newswire)
Oct-03-23 04:05PM	Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (PR Newswire) -6.51%
Oct-02-23 08:00AM	Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer (PR Newswire) -11.16%
Sep-20-23 04:30PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-05-23 08:00AM	Aadi Bioscience to Participate at Upcoming Investor Conferences (PR Newswire) -6.31%
Aug-09-23 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update (PR Newswire) -6.85%
Aug-02-23 08:00AM	Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update (PR Newswire)
May-25-23 05:30PM	Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
May-23-23 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Events (PR Newswire)
May-10-23 08:00AM	Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial (PR Newswire) -16.61%
May-03-23 08:00AM	Aadi Bioscience to Report First Quarter 2023 Results and Operational Update (PR Newswire)
Apr-26-23 04:05PM	Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-14-23 01:00PM	Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-06-23 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 (PR Newswire)
Mar-28-23 08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update (PR Newswire) -5.52%
Mar-27-23 08:00AM	Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors (PR Newswire)
Mar-26-23 02:00PM	Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer (PR Newswire)
Mar-15-23 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update (PR Newswire)
Mar-03-23 08:00AM	Aadi Bioscience Announces Leadership Transition (PR Newswire) -14.51%
Feb-22-23 08:00AM	Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Nov-17-22 08:00AM	Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting (PR Newswire)
Nov-09-22 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update (PR Newswire)
Nov-08-22 04:00PM	Aadi Bioscience Announces Planned Leadership Transition (PR Newswire)
Nov-03-22 08:00AM	Aadi Bioscience to Present at Upcoming Investor Conferences (PR Newswire)
Oct-27-22 08:00AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
Oct-12-22 08:01AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
08:00AM	Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation (PR Newswire)
Sep-22-22 04:01PM	Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing (PR Newswire) +8.06%
Sep-01-22 08:00AM	Aadi Bioscience Announces Participation in Upcoming September Investor Conferences (PR Newswire)
Aug-10-22 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update (PR Newswire)
Aug-04-22 06:21AM	Is Aadi Bioscience, Inc. (NASDAQ:AADI) Popular Amongst Insiders? (Simply Wall St.)
Jul-28-22 08:30AM	Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update (PR Newswire)

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lennon David James	CHIEF EXECUTIVE OFFICER	Mar 02 '26	Sale	3.31	5,100	16,879	44,579	Mar 10 07:36 PM
Giacobello Scott M.	CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	3.31	2,594	8,585	28,100	Mar 10 07:36 PM
BALL BRYAN	See remarks	Mar 02 '26	Sale	3.31	1,834	6,070	206,019	Mar 10 07:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WHWK

Whitehawk Therapeutics Inc

Upgrade your FINVIZ experience